NIGP 26916: Blood Derivatives

NIGP 26916 Blood Derivatives, an Item code, covers specialized blood products derived from donated plasma and whole blood, including clotting factors, immunoglobulins, albumin, and other therapeutic concentrates that state and local health systems, hospitals, and public health agencies procure for clinical use. State and local governments purchase these products primarily through established supplier relationships and standing orders rather than competitive solicitations, reflecting the regulated nature of blood product sourcing, the critical role these products play in trauma care and chronic disease management, and the requirement that suppliers maintain rigorous FDA licensure and blood-banking certifications.

The source provided contains no recent state and local contract opportunities under NIGP 26916. Blood derivatives procurement typically occurs through blanket purchase orders, cooperative purchasing agreements, and direct awards to licensed blood banks and plasma manufacturers rather than through open RFP, RFQ, IFB, or ITB processes. State health departments, county hospital systems, and municipal trauma centers are the primary buying entities, but the absence of posted solicitations in the recent-opportunities block suggests that meaningful market activity under this code takes place outside the standard procurement-notice channels that business development professionals typically monitor.